Gene-Disorder Association · Article
First reported
1950
Supporting publications
2
Approved treatment annotated
Association Review
In brief
The association between HCP5 (HLA Complex P5) and Pancreatic Cancer is reported, supported by a single source.
Sources
1
Clinical variants
0
Symptoms
35
Compounds
1
Trials
747of 2,668 via HCP5 compounds
Publications
2
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
03
Pancreatic Cancer
The disorder
33 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
04
Phenotype
Clinical features
26 clinical features
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access
05
Population genetics
GWAS signals
1 GWAS phenotype
Gene-associated GWAS phenotypes matching the disorder, with best SNP, score, risk-allele frequency and effect size.
Request access
06
Interventions
Therapeutics
1 compound or drug
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials
2,668 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
2 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
09
Provenance
References & sources
10 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access